Oliver Sol

Directeur Technique/Scientifique/R&D chez AC IMMUNE SA

58 ans

Health Technology

Consumer Services

Postes actifs de Oliver Sol

Sociétés	Poste	Début	Fin
AC IMMUNE SA	Directeur Technique/Scientifique/R&D	-	-
AC IMMUNE SA	Corporate Officer/Principal	-	-

Sociétés	Poste	Début	Fin
EUROBIO SCIENTIFIC	Directeur Technique/Scientifique/R&D	-	-
EUROBIO SCIENTIFIC	Conseiller Juridique Général	-	-
Exonhit Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.	Directeur Technique/Scientifique/R&D	-	-

Internationale

France	4
Suisse	2

Opérationnelle

Chief Tech/Sci/R&D Officer	3
Corporate Officer/Principal	1
General Counsel	1

Sectorielle

Health Technology	4
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
AC IMMUNE SA	Health Technology
EUROBIO SCIENTIFIC	Health Technology

Entreprise privées	2
Exonhit Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.	Health Technology
Université de Paris XI Paris Sud	Consumer Services

Entreprise privées

Health Technology

Université de Paris XI Paris Sud

Consumer Services